A medical device comprising: an array of microneedles and a coating disposed on the microneedles wherein the coating comprises: a local anesthetic selected from the group consisting of lidocaine prilocaine and a combination thereof; and a local anesthetic dose-extending component selected from the group consisting of tetracaine ropivacaine bupivacaine procaine and a combination thereof; wherein the local anesthetic is present in an amount of at least 1 wt-% based upon total weight of solids in t...

Compositions having a mixture of lidocaine prilocaine and tetracaine or their pharmaceutically acceptable salts. A preferred composition includes the following components in the indicated approximate w/w percentages: 1.5% lidocaine base; 1.5% prilocaine base; 4% tetracaine base and water. In some implementations also included may be about 10% methylpynrolidone; 2% dimethyl sulfoxide; 0.08% topical hyaluronidase; 1.5% guar gum; 1% polyoxyethylenesorbitan monolaurate; 0.5 polyoxyethylenesorbitan m...

PURPOSE: A transdermal formulation is provided to remarkably enhance skin permeability of lidocaine and to suppress skin permeability of prilocaine in a proper level, thereby preventing side effects caused by excessive administration of prilocaine. CONSTITUTION: A transdermal formulation contains a mixture containing lidocaine or a salt thereof and prilocaine or a salt thereof mixed in a weight ratio of 5:1-1.4:1. The mixture is an eutetic mixture of lidocaine or the salt thereof and prilocaine ...

A medical device, comprising: an array of microneedles, and a coating disposed on the microneedles, wherein the coating comprises: a local anesthetic selected from the group consisting of lidocaine, prilocaine, and a combination thereof

The present invention concerns new preservative-free hyperbaric compositions of prilocaine HCI intended for use in intrathecal narcosis characterized by high stability at ambient temperature (15~C-27~C). The present invention also concerns a method for manufacturing said compositions.

The present embodiments relate to topically delivered compounded medications. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include low concentrations of local anesthetics, a NSAID, an anticonvulsant, and/or other active ingredients. The transdermal cream may include lidocaine, prilocaine, meloxicam, and lamotrigine and/or topiramate. Alternatively, the transdermal cream may include a lidocaine/prilocaine ba...

The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethi...

The present embodiments may relate to topically delivered compounded medications for the treatment of scar tissue, skin disorders, and/or other ailments. In one aspect, a transdermal cream or gel may provide for the effective administration of multiple medications simultaneously. Preferably, a silicone-based gel may be provided as a base composition and may have a non-zero percentage of silicone or silicone variant. The silicone-based gel may comprise cyclopentasiloxane, polysilicone-11, dimethi...

The invention relates to a composition of matter comprising hyaluronic acid and/or a pharmaceutically acceptable hyaluronate salt, cross-linked hyaluronic acid and/or a pharmaceutically acceptable cross-linked hyaluronate salt, and prilocaine and/or a pharmaceutically acceptable salt thereof, and optionally at least one additive.